A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C
NCT ID: NCT00940420
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
2695 participants
INTERVENTIONAL
2002-10-31
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Copegus (ribavirin)
800 - 1200 mg po daily for 24 weeks
peginterferon alfa-2a [Pegasys]
180 mcg sc once weekly for 24 weeks
B
Copegus (ribavirin)
800 - 1200 mg po daily for 48 weeks
peginterferon alfa-2a [Pegasys]
180 mcg sc once weekly for 48 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Copegus (ribavirin)
800 - 1200 mg po daily for 24 weeks
Copegus (ribavirin)
800 - 1200 mg po daily for 48 weeks
peginterferon alfa-2a [Pegasys]
180 mcg sc once weekly for 24 weeks
peginterferon alfa-2a [Pegasys]
180 mcg sc once weekly for 48 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* serologic evidence of chronic hepatitis C infection
* compensated liver disease
* negative pregnancy test and in both males and females use of 2 forms of contraception during study and 6 months after treatment
Exclusion Criteria
* hepatitis A, hepatitis B or HIV infection
* hepatocellular carcinoma
* severe concomitant disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Afula, , Israel
Ashkelon, , Israel
Bat Yam, , Israel
Beersheba, , Israel
Hadera, , Israel
Haifa, , Israel
Haifa, , Israel
Haifa, , Israel
Holon, , Israel
Jerusalem, , Israel
Kfar Saba, , Israel
Nahariya, , Israel
Nazareth, , Israel
Petah Tikva, , Israel
Petah Tikva, , Israel
Ramat Gan, , Israel
Rehovot, , Israel
Safed, , Israel
Tel Aviv, , Israel
Ẕerifin, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML16837
Identifier Type: -
Identifier Source: org_study_id